IPIC - the obesity pill stock Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC - the obesity pill stock

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pat Shields who wrote (107)	9/30/1996 10:58:00 PM
From: Anthony Tran	of 113

Pat and Margaret, Alexander Haig is currently on both American On Line and IPIC board of directors. He plays very critical in lobbying for both companies. If you red the REDUX article in Time you will see that some people question the role of Alexander in the approval of REDUX. It is certainly a plus to have him on the board of director; certainly IPIC knows who to pick as a big gun. Vector Securities analyst Michael King said " that IPIC's REDUX will have a monopoly in this market place for obeisity drug for at least another year after the FDA panel recommended against approval of Knoll Pharmaceutical Meridia sibutramine. Because of Meridia's side effect of increasing blood pressure one half of the obese patients is not eligeable for the drug. Also Meridia had a high drop out rate and the same effect as REDUX", therefore we can kiss good bye at least to Knoll's product. I am currently looking for IPIC to be back in the mid 40 and the future is great for this company. I personnally do not see any competition fro REDUX for at 2-3 yeras. and its division Intercardia and Progenitor have a great drug pipeline. Anthony Tran

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next